PrimeVigilance is pleased to share ERGOMED plc Press Release and to part of front against coronavirus
30 March 2020.
Our united front: PrimeVigilance response to Zagreb earthquake
23 March 2020.
Our United Front : Ergomed Plc Response to COVID-19
21 March 2020.
Guildford, UK – 18 March 2020: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, today announces the initiation of a study of siltuximab, an interleukin (IL)-6 targeted monoclonal antibody, for the treatment of patients with COVID-19 who have developed serious respiratory complications (Siltuximab In Serious COVID-19; SISCO Study). The study is sponsored by the Papa Giovanni XXIII Hospital in Bergamo, Italy and supported by EUSA Pharma (EUSA) (see announcement below).
18 March 2020.
PrimeVigilance is delighted to share the exciting news about an investment PrimeVigilance, part of Ergomed plc. has made in order to significantly expand our expert service supporting all products in major pharmaceutical markets around the world.
13 January 2020.
PrimeVigilance, an Ergomed company is pleased to promote the upcoming unique and highly focused ISoP two-days seminar, that will explore process automation and AI in the Pharmacovigilance Lifecycle, The topic will be debated by a team of specialists, chaired by Dr Jan Petracek, PrimeVigilance Strategic Advisor and an ISoP Board member.
14 November 2019.
+44 (0)1483 307920
(+1) 781 703 5540
United Kingdom (Head Office)